PO.ET07.02 · 实验与分子治疗

用于探索患者来源癌细胞系药物基因组学的CellMiner跨数据库（CellMinerCDB）

CellMiner Cross-Database (CellMinerCDB) for Exploration of Patient-Derived Cancer Cell Line Pharmacogenomics

编号 3138 展板 6 时间 4/20 02:00–05:00 区域 Section 18 主讲 Fathi Elloumi, PhD

分会场 Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy

查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Fathi Elloumi¹, William C. Reinhold², Sudhir Varma³, Yanghsin Wang¹, Meric Kinali⁴, Yashuhiro Arakawa⁵, Yoshitaka Inoue⁶, Mirit Aladjem¹, Yves Pommier¹, Augustin Luna⁷

¹National Cancer Institute, Bethesda, MD,²National Cancer Institute, Rockville, MD,³HiThru Analytics LLC, Princeton, NJ,⁴University of Massachusetts-Boston, Boston, MA,⁵Jikei University, Tokyo, Japan,⁶National Library of Medicine,, Bethesda, MD,⁷National Library of Medicine, Bethesda, MD

摘要 Abstract

中文摘要

CellMiner跨数据库（CellMinerCDB）（https://discover.nci.nih.gov/cellminercdb/）是一款成熟的交互式应用程序，无需丰富的编程经验即可直接访问并探索癌细胞系药物基因组学。数据汇编自多个来源，包括美国国家癌症研究所（NCI）、Broad研究所DepMap、Sanger/MGH GDSC、MD安德森癌症中心（MDACC）MCLP以及美国国家转化科学促进中心（NCATS）细胞系项目。在2.2版本更新中，我们的数据集已扩展至1,916个癌细胞系和超过25,000种药物的药物基因组学数据。药物筛选数据包括来自Broad PRISM、NCATS和NCI的许多可用于潜在药物再利用的额外化合物。用户界面便于发现感兴趣的特定样本并跨数据库识别药物和细胞系。我们还扩展了用于交叉引用其他数据库以及下载数据供进一步癌症生物学和药物发现研究的注释。在此，我们提供了CellMinerCDB的应用案例，包括（i）鉴于细胞系、基因和药物在数据库间的重叠而进行的数据可重复性；（ii）候选生物标志物发现；以及（iii）跨数据集分析。

查看英文原文 English abstract

CellMiner Cross-Database (CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is an established interactive application providing direct access and enabling exploration of cancer cell line pharmacogenomics without extensive programming experience. Data are compiled from many sources, including the National Cancer Institute (NCI), Broad Institute DepMap, Sanger/MGH GDSC, MD Anderson Cancer Center (MDACC) MCLP, and National Center for Advancing Translational Sciences (NCATS) cell line projects. In the version 2.2 update, our collection has expanded to pharmacogenomics data for 1,916 cancer cell lines and over 25,000 drugs. Drug screening data include many additional compounds for potential drug repurposing from the Broad PRISM, NCATS, and NCI. The user interface facilitates uncovering specific samples of interest and identifying drug and cell lines across databases. We also expanded the annotations for cross-referencing other databases and downloading our data for further cancer biology and drug discovery studies. Herein, we provide use cases for CellMinerCDB including (i) data reproducibility given overlaps of cell lines, genes, and drugs across databases; (ii) candidate biomarker discovery; and (iii) cross-dataset analyses.

利益披露 Disclosure

F. Elloumi, None.. S. Varma, None.. Y. Wang, None.. M. Kinali, None.. Y. Arakawa, None.. Y. Inoue, None.. Y. Pommier, None.. A. Luna, None.

← 返回 AACR 2026 检索